Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System

Area of Science:

• Immunology
• Pharmacology
• Drug Development

Background:

• Drug hypersensitivity (DH) reactions are unusual immune responses not driven by antigens.
• Current understanding suggests non-covalent drug-protein binding triggers DH via mechanisms like the p-i concept, enhanced affinity, or fake antigen models.

Approach:

• Discusses challenges in detecting labile, non-covalent drug-protein interactions early in drug development.
• Proposes a combined approach using in vitro cell culture assays with HLA-typed cells, functional analyses, and computational structural analysis.
• Highlights the need for integrating diverse data to assess risks associated with drug-protein interactions.

Key Points:

• Non-covalent drug-protein binding is a key mechanism in drug hypersensitivity.
• Detecting these interactions is challenging due to immune system diversity and interaction variability.
• A multi-faceted approach combining in vitro assays, functional analysis, and computational methods is proposed.

Conclusions:

• Novel models of DH necessitate revised risk assessment strategies in drug development.
• Early detection of immunologically relevant drug-protein interactions is crucial.
• Clinical monitoring is essential to validate findings and understand in vivo factors influencing DH manifestation.